Standout Papers

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias 2006 2026 2012 2019 1.3k
  1. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias (2006)
    Moshe Talpaz, Neil P. Shah et al. New England Journal of Medicine
  2. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (2010)
    Hagop M. Kantarjian, Neil P. Shah et al. New England Journal of Medicine
  3. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL (2006)
    Hagop M. Kantarjian, Francis J. Giles et al. New England Journal of Medicine
  4. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet (2009)
    Michele Baccarani, Jörge E. Cortes et al. Journal of Clinical Oncology
  5. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis (2010)
    Srđan Verstovšek, Hagop M. Kantarjian et al. New England Journal of Medicine
  6. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia (2005)
    Michael J. Keating, Susan O’Brien et al. Journal of Clinical Oncology
  7. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies (2003)
    Jean‐Pierre J. Issa, Guillermo Garcia‐Manero et al. Blood
  8. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016)
    Jörge E. Cortes, Giuseppe Saglio et al. Journal of Clinical Oncology
  9. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia (2000)
    Hagop M. Kantarjian, Susan O’Brien et al. Journal of Clinical Oncology
  10. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (2010)
    Amie S. Corbin, Anupriya Agarwal et al. Journal of Clinical Investigation
  11. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents (2013)
    Hui Yang, Carlos E. Bueso‐Ramos et al. Leukemia
  12. Acute myeloid leukaemia (2018)
    Nicholas J. Short, Michael Rytting et al. The Lancet
  13. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012)
    Jörge E. Cortes, Hagop M. Kantarjian et al. New England Journal of Medicine
  14. Molecular biology of bcr-abl1–positive chronic myeloid leukemia (2008)
    Alfonso Quintás‐Cardama, Jörge E. Cortes Blood
  15. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia (2006)
    Hagop M. Kantarjian, Yasuhiro Oki et al. Blood
  16. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia (2008)
    Constantine S. Tam, Susan O’Brien et al. Blood
  17. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) (2011)
    Hagop M. Kantarjian, Neil P. Shah et al. Blood
  18. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (2018)
    Jörge E. Cortes, Florian H. Heidel et al. Leukemia
  19. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis (2015)
    Animesh Pardanani, Claire Harrison et al. JAMA Oncology
  20. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial (2017)
    Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 9 from Science/Nature 111 standout
Sub-graph 1 of 18

Citing Papers

Cancer statistics, 2022
2022 Standout
TIM-3 restrains anti-tumour immunity by regulating inflammasome activation
2021 StandoutNature
5 intermediate papers

Works of Jörge E. Cortes being referenced

Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)
2016 Nobel
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
2006
and 25 more

Author Peers

Author Last Decade Papers Cites
Jörge E. Cortes 58990 40429 19371 23185 2.2k 82.8k
Hagop M. Kantarjian 94163 62640 24904 43493 3.3k 144.3k
Moshe Talpaz 28654 22419 12929 10816 765 44.0k
Brian Druker 29898 21325 13369 17055 597 54.0k
Guillermo Garcia‐Manero 29771 14343 4360 17388 1.5k 42.9k
Francis J. Giles 20046 15414 6250 14728 778 41.0k
Ayalew Tefferi 34157 37379 15562 21733 1.1k 53.3k
Andreas Hochhaus 29429 23691 15371 5953 819 39.2k
Susan O’Brien 20888 16969 5501 8142 837 35.7k
Robert A. Kyle 33182 12253 2953 34291 1.0k 58.3k
Clara D. Bloomfield 28029 11828 2078 17444 400 42.0k

All Works

Loading papers...

Rankless by CCL
2026